<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862355</url>
  </required_header>
  <id_info>
    <org_study_id>DOX_2I_1476_09</org_study_id>
    <nct_id>NCT00862355</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence study of SPARC147609
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90% confidence interval of the relative mean Cmax, AUC0-t, AUC0-∞, of the test and reference product</measure>
    <time_frame>2 cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPARC147609</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference147609</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC147609</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference147609</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects meeting all of the following criteria will be considered for enrollment in
             the study:

               -  Availability of subject for the entire study period and willingness to adhere to
                  protocol requirements.

               -  Patients with documented diagnosis of Ovarian Cancer and eligible for receiving a
                  dose 50mg/m2 of Doxorubicin liposome(preferably on no other concomitant
                  medication, however, if considered necessary, to be documented and given).

               -  Patients at least 18-years of age or older. iv. Subjects who have no evidence of
                  underlying disease (except ovarian cancer) during screening medical history and
                  whose physical examination is performed within 21 days prior to commencement of
                  the study.

               -  Patients with Performance ≤ 2 on the ECOG performance scale. vi. Subjects whose
                  screening laboratory values are within normal limits or considered by the
                  clinical Investigator/Co-Investigator to be of no clinical significance.

               -  Informed consent form given in written form.

        Exclusion Criteria:

          -  History or presence of significant:

               -  Allergy or Significant history of hypersensitivity or idiosyncratic reactions to
                  Doxorubicin Hydrochloride and/or any related compounds etc.

               -  Cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine,
                  immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.

               -  Alcohol dependence, alcohol abuse or drug abuse or addiction with any
                  recreational drug within past one year.

               -  Clinically significant illness (except ovarian cancer)within 4 weeks before the
                  start of the study v. Positive result to HIV, HCV, RPR and HBsAg.

               -  Use of enzyme-modifying drugs (like Phenytoin, Carbamazepine, Barbiturates,
                  Gresiofulvine etc.) in the previous 30 days before day 1 of this study and during
                  the study.

          -  Donation of 350 mL or more of blood in the previous 90 days before day 1 of this
             study.

          -  Participation in another clinical trial within the preceding 90 days of study start

          -  Subjects who have:

               -  Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg

               -  Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg

               -  Pulse rate below 60/min. or above 100/min
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC Site 1</name>
      <address>
        <city>Hyderabaad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma</keyword>
  <keyword>Ovary</keyword>
  <keyword>Carcinoma Ovary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

